DPP4 and diabetes mellitus: and therefore these substances should be considered in addition to metformin in patients with diabetes and known LLPAD.46,47 Another example is the selective incretin based dipeptidyl peptidase 4 (DPP-4) inhibitors used in diabetes, which did not demonstrate reduction of MACE or MALE in patients with LLPAD.